Literature DB >> 612214

Tumor-associated hyperamylasemia.

J E Berk, J Shimamura, L Fridhandler.   

Abstract

Studies were made in eight patients with hyperamylasemia associated with cancer of the lung, pancreas or colon. Isoamylase analysis, conducted in seven of the eight patients revealed that the dominant isoamylase component was S-type in three and P-type in three; in one patient both isoamylases were elevated about equally. Examination of the serum or urine of the same seven patients for subcomponent isoamylase disclosed the presence in two of the seven of an unusual isoamylase designated "Y-type". This subcomponent isoamylase was also found in some samples of human milk, but not in normal persons or in patients with a variety of disorders other than cancer. The significance of hyperamylasemia occurring in association with cancers, the factors responsible for the variability in isoamylase pattern in those with hyperamylasemia, and the relationship, if any, of the "Y" isoamylase form to cellular growth and replication are all presently obscure and remain to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 612214

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  3 in total

1.  Phaeochromocytoma with transient hyperamylasaemia during hypertensive crisis.

Authors:  J Yamanishi; M Nishikawa; Y Ohomori; Y Furuta; H Fukuzaki
Journal:  Br Med J (Clin Res Ed)       Date:  1985-10-26

2.  Hyperamylasemia and S-type isozyme dominance in liver cirrhosis.

Authors:  Y Hatta; N Yoshikawa; H Funatomi; S Taguchi
Journal:  Int J Pancreatol       Date:  1987 Oct-Dec

3.  LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial.

Authors:  William M Steinberg; Michael A Nauck; Bernard Zinman; Gilbert H Daniels; Richard M Bergenstal; Johannes F E Mann; Lasse Steen Ravn; Alan C Moses; Mette Stockner; Florian M M Baeres; Steven P Marso; John B Buse
Journal:  Pancreas       Date:  2014-11       Impact factor: 3.327

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.